SOURCE: TheraBiogen Inc.

September 23, 2010 14:57 ET

TheraBiogen Announces Shipment of and Additional Orders for Its TheraMax® Nasal Spray Products From Rite Aid Corporation

NEW YORK, NY--(Marketwire - September 23, 2010) -  TheraBiogen, Inc. (OTCBB: TRAB) announced today that it has shipped its first order of its TheraMax® Cold & Flu and TheraMax® Allergy relief sprays and has received additional orders for those nasal spray products from Rite Aid corporation with nationwide distribution for retail sales of the products during the Fall cold and flu season. This represents orders for both the TheraMax® Cold & Flu relief spray and the TheraMax® Allergy relief spray. Both nasal spray products are already on or will be on the shelves at all of the pharmacy chain's retail locations. 

About TheraBiogen, Inc.

TheraBiogen, Inc. is the manufacturer and distributor of homeopathic nasal sprays for aiding in the relief of cold, flu and allergies. The products are made from natural, homeopathic ingredients and contain no zinc, which has been identified as potentially causing nasal problems in other similar products on the market. For further information please visit

Safe Harbor Statement

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21 E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that these forward-looking statements involve uncertainties and risk that could cause actual performance and results of operations to differ materially from those anticipated. These risks and uncertainties include issues related to the ability to: obtain sufficient funding to continue operations, maintain adequate cash flow, profitably exploit new ventures, as well as other factors set forth in the Company's most recently filed Form 10-K and Form 10-Q reports. The forward looking statements contained herein represent the Company's judgment as of the date of this release and it cautions readers not to place undue reliance on such statements. TheraBiogen, Inc. assumes no obligation to update the statements contained in this release except as required by applicable securities disclosure rules.

Contact Information

  • Contact information:
    Kelly T. Hickel
    TheraBiogen, Inc.
    Telephone: 646-808-3095
    Email Contact